



Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae

A i 'h!g]H'; fUa !BY[Uhj Y'Gi fj Y]'UbWV-b]hUhj YfA i ; G-L

Form Approved OMB No. 0920-0978

< YUk WUfY-5 ggcWUH'X-bZVWjcs'7 ca a i b]m-bHyfZUW'fk 5 7 L7 UgY F Ydcf h

Patient's Name: _____ Phone no. () _____

Address: _____ MRN: _____

City: _____ State _____ ZIP: _____ Hospital: _____

---Patient Identifier information is not transmitted to CDC---

8 9 AC ; F 5 D < 7 G

Form with multiple text input fields for patient information.

Demographic information section including gender, ethnicity, and race.

Antibiotic resistance section: 10. CF; 5 B-GA. Extended-Spectrum Cephalosporin-resistant: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca.

Specimen collection site section with checkboxes for various body sites.

Facility information section with checkboxes for various facility types and transfer status.

ICU admission section with checkboxes for admission status and date of admission.

Outcome section: 16. D5 H9 BH CI H7 CA9. Survived or Died, with discharge/death dates and location.

Public reporting burden of this collection of information is estimated to average 28 minutes per response...



Section 18: Infection. Includes checkboxes for abscess, cellulitis, meningitis, pneumonia, etc.

Section 19: Chronic Conditions. Includes checkboxes for cystic fibrosis, diabetes, heart disease, liver disease, etc.

Section 20: Substance Use. Includes checkboxes for smoking, alcohol abuse, and other substances like marijuana, opioids, etc.

Section 21: Discharge and Catheters. Includes checkboxes for discharge date, central line, and various catheter types.

Section 22: Weight. Includes fields for weight in lbs, oz, kg and height in ft, in, cm.

Section 23: Travel and Hospitalization. Includes checkboxes for international travel and hospitalization while visiting other countries.



I F-B9 71 @H F9G' CB@M &2" F97 CF8 'H<9' 7C @BM7 CI BH.

I F-B9 71 @H F9G'CB@M & . G= BG5 B8 'GMADHCAG5 GGC7-5 H98 'K H<' I F-B9 71 @H F9"

Please indicate if any of the following symptoms were reported during the 5 day time period including the 2 calendar days before through the 2 calendar days after the DISC.

- BcbY □ I b_bck b
□ Costovertebral angle pain or tenderness □ Frequency
□ Dysuria □ Suprapubic tenderness
□ Fever [temperature ≥ 100.4 °F (38 °C)] □ Urgency
Symptoms for patients ≤ 1 year of age only:
□ Apnea
□ Bradycardia
□ Lethargy
□ Vomiting

&4U" =G5 BH A 7 FC6-5 @ G9 'fW' CF CF5 @-B 'H<9' '\$85 MG'69: CF9 'H<9' 8-G7 '8C7I A9 BH983' □ Yes □ No □ Unknown

&4V" = 'M9 GZ7 <9? '5 @@5 BH A 7 FC6-5 @G1 G98 'B 'H<9' '\$85 MG'69: CF9 'H<9' 8-G7 . fW \ YW 'U' 'h UhUdd nL'..... □ Unknown

- Amikacin □ Cefazidime □ Eravacycline □ Polymyxin B
□ Amoxicillin □ Cefazidime/avibactam □ Fidaxomicin □ Polymyxin E (colistin)
□ Amoxicillin/clavulanic acid □ Ceftizoxime □ Fosfomicin □ Rifaximin
□ Ampicillin □ Ceftolozane/tazobactam □ Gentamicin □ Tedizolid
□ Ampicillin/sulbactam □ Ceftriaxone □ Imipenem/cilastatin □ Telavancin
□ Azithromycin □ Cefuroxime □ Levofloxacin □ Tigecycline
□ Aztreonam □ Cephalixin □ Linezolid □ Tobramycin
□ Cefazolin □ Ciprofloxacin □ Meropenem □ Trimethoprim
□ Cefdinir □ Clarithromycin □ Meropenem/vaborbactam □ Trimethoprim/sulfamethoxazole
□ Cefepime □ Clindamycin □ Metronidazole □ Vancomycin
□ Cefiderocol □ Dalbavancin □ Moxifloxacin □ IV
□ Cefixime □ Daptomycin □ Nitrofurantoin □ PO
□ Cefotaxime □ Delafloxacin □ Oritavancin □ Other (specify):
□ Cefoxitin □ Doripenem □ Penicillin □ Other (specify):
□ Cefpodoxime □ Doxycycline
□ Ceftaroline □ Ertapenem □ Piperacillin/tazobactam

REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.

&5a" DID 'H<9' D5 H9 BH HAVE A POSITIVE TEST(S) FOR 'G5 FGI7 cJ1 & fA C @71 @ F '5 G65 MZ G9 FC @; MCF' CH<9 F '7 CB: -F A5 HCFMH9 GH 'CB' CF' 69: CF9 'H<9' 8-G7 3'

&5b. IF YES, COMPLETE TABLE BELOW:

- Yes
□ No
□ Unknown

Table with 3 columns: Test result, Specimen collection date, Test type. Rows for FIRST positive test and MOST RECENT positive test for SARS-CoV-2 on or before the DISC.

&5W 7 CJ-8 IB9H75 G9 -8.

&5X" BB8 GG-8 g fD @5 G9' DFCJ-89 '5 H' @5 GH CB9 C: 'H<9' : C @C K -B; 'K <9 B '5 DD @7 5 6 @L

@WU' cUgY-8.
@WU' rYw fX'-8.
GHUH' VUgY' X Y b H Z Yf.
@[UHhVUgY' X Y b H Z Yf.
CDC 2019-nCoV ID: _____

&6U" K 5 G'H<9' -B7 -8 9BH' GD97 -A9B' DC @MA 7 FC6-5 @

&6V" K <5 H'G7 F99B-B; #7 CB: -F A5 HCFM A9H<C8 'K 5 G'I G98 ': CF '9 G6 @ IDENTIFICATION3' (Check all that apply): □ None □ Unknown

&6W" = 'G7 F99B-B; #7 CB: -F A5 HCFM A9H<C8 'K 5 G'I G98 ZK <5 H'K 5 G'H<9' F9GI @B

- Yes
□ No
□ Unknown

- Broth Microdilution (ATI detection)
□ ESBL well
□ Expert rule (ATI flag)
□ Unknown
□ Broth Microdilution (Manual)
□ Disk Diffusion
□ E-test
□ Molecular test (specify):
□ Other non-molecular test (specify):

- Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown
□ Positive □ Negative □ Indeterminate □ Unknown



2+ "GI G7 9DH6 =GHMF9GI @HG.

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available

8 UH Gci fVW	Medical Record		Microscan		Vitek		Phoenix		Sensititre		Kirby-Bauer		E-test	
5 bhjVjchjW	A 7	hifd	A 7	hifd	A 7	hifd	A 7	hifd	MIC	Interp	Zone Diam	Interp	MIC	Interp
5 a j_UWj														
5 a cl jW j b#`Uj i`UbUH														
5 a d jW j b														
5 a d jW j b#Gi`VUWLa														
5 nfYcbLa														
7 YZjnc`j b														
7 9: 9D=A9														
7 YZXYfcVc`														
7 9: CH5 L=A9														
7 YZ: l j j b														
7 9: H5 N8 =A9														
7 YZUhjXja Y# j jVUWLa														
7 YZc`cnUbY#HuncVUWLa														
7 9: HF-5 LCB9														
7 Yd\ Uch j b														
7 jdfcZcl UWj b														
7 C @GH-B														
8 CF=D9 B9 A														
8 cl nWwVj bY														
9 fUj UWwVj bY														
9 FH5 D9 B9 A														
: cgZ: a nWj b														
; YbHLa jWj b														
=A=D9 B9 A														
=a j dYbYa !fY VUWLa														
@j cZcl UWj b														
A9 FCD9 B9 A														
A YfcdYbYa !j UVcfVUWLa														
A jbcWwVj bY														
B jfcZ fUhc j b														
Ca UXUWwVj bY														
D j dYf UWj b#HuncVUWLa														
D`Unca jWj b														
DC @MA ML-B`6														
F jZLa d j b														
HYf UWwVj bY														
H; 97 M7 @B9														
Hc VfLa nWj b														
Trimethoprim-sulfamethoxazole														

28a. WAS CASE FIRST IDENTIFIED THROUGH AUDIT? Yes No

28b. CRF STATUS: Complete Pending Chart unavailable after 3 requests

28c. SO INITIALS: _____

28d. DATE OF ABSTRACTION: _____

28e. COMMENTS:

